This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price.
Rory Martin, PhD
Advertisement
Rory Martin, PhD, Gross to Net and 340B Analytics & Thought Leadership, IQVIA Market Access Technology Solutions
ORCID ID: 0000-0002-7216-4245
Articles by Rory Martin, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
How Often Do Health Insurers Deny Doctor-Recommended Care?
2
Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM
3
Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention
4
Oz White House Briefing Touts Drug Savings and Fraud Cleanup, but Data Tell a Nuanced Story
5